More Details on This News

CORONA Remedies Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2025.

The company reported a consolidated revenue from operations of ₹361.13 crore for Q2 FY26 and ₹707.67 crore for H1 FY26. This represents a year-on-year growth of 15.1% for the quarter and 17.0% for the half-year.

Profit After Tax (PAT) for Q2 FY26 stood at ₹52.32 crore, an increase of 21.8% year-on-year. For H1 FY26, PAT was ₹98.52 crore, marking a growth of 35.1% year-on-year. The company also highlighted healthy return ratios, with an annualized RoE of 31.1% and RoCE of 49.7% for H1 FY26.

Mr. Nirav K. Mehta, Managing Director and CEO, expressed satisfaction with the strong financial performance, attributing it to consistent strategy, disciplined execution, and a focus on core therapeutic segments. He noted that the company outperformed the IPM growth and the market by strengthening its field force, expanding its brand portfolio, and focusing on specialist prescriptions.

CORONA Remedies Limited will hold an earnings call on January 05, 2026, at 12:00 PM IST to discuss its financial and business performance. The company is an India-focused branded pharmaceutical formulation company involved in women's healthcare, cardio-diabeto, pain management, and other therapeutic areas, with WHO-GMP/EU GMP-certified manufacturing facilities and two DSIR-approved R&D centers.